The 3 companies enter Licensing Agreement for Antibody Drug Conjugate program.
Both companies joined their forces to develop Treatments for COVID- 19 Pneumonia and Other Disorders.
Bispecific κλ bodies targeting CD47 and membrane proximal epitopes on MSLN afford enhanced efficacy in vitro and in vivo.
Light Chain Bioscience is leveraging its proprietary bispecific antibody format to advance immune therapies in oncology and beyond.
Light Chain Bioscience successfully completes Factor VIII mimetic bispecific antibody discovery for Takeda.
